Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Relmada Therapeutics Announced The Dosing Of The First Patient In The Relight (Study 304) Phase 3 Trial Evaluating REL-1017 As An Adjunctive Treatment Of Major Depressive Disorder

Author: Benzinga Newsdesk | August 23, 2023 07:31am

Posted In: RLMD